logo
  

GEA FY21 Profit Rises; Revenue Up 4.3% On Organic Basis

GEA (GEAGF.PK,GEAGY.PK) reported that its fiscal 2021 EBITDA before restructuring expenses increased by 17.3 percent to 624.8 million euros from prior year. The corresponding EBITDA margin improved by 1.8 percentage points to 13.3 percent. Earnings per share before restructuring expenses was 1.99 euros compared to 1.03 euros.

Profit increased to 305.2 million euros from 96.8 million euros, prior year. Earnings per share increased to 1.70 euros from 0.54 euros.

Order intake increased by 11 percent to 5.22 billion euros. Organic growth stood at 14 percent. Revenue increased by 1.5 percent to 4.70 billion euros. Revenue rose by 4.3 percent on an organic basis.

For fiscal 2022, the company projects organic revenue growth of more than 5 percent. EBITDA before restructuring expenses at constant exchange rates is expected to be in a range between 630 million euros and 690 million euros. The company also confirmed its medium-term financial targets.

A dividend of 0.90 euros per share, 5 cents more than prior year, will be proposed to the Annual General Meeting.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Longmont Colorado -based Royal Crest Dairy is recalling 2% Chocolate Milk citing the potential to be contaminated with undeclared egg, a known allergen, the U.S. Food and Drug Administration said. The recall involves Farmer's 2% Reduced Fat Chocolate Milk Pints with the code date of AUG-22. ANI Pharmaceuticals, Inc. (ANIP) Monday announced a wider loss for the second quarter, despite a 52 percent surge in revenues. For the full year 2022, the company reiterated the adjusted earnings per share range, revenue guidance and raised Cortrophin revenue outlook. The company reported a quarterly... Shares of BioNTech SE were losing around 4 percent in the morning trading in Germany and around 5 percent in the pre-market activity on Nasdaq after the German Covid-19 vaccine maker reported sharp drop in profit and revenues for the second quarter. However, the company recorded strong growth in first-half results. Further, the company maintained BioNTech COVID-19 vaccine revenue guidance
Follow RTT